Quality Control Measures Lead to Blacklisting Notice for Pharmaceutical Firm in Chhattisgarh

The Chhattisgarh health department’s commitment to ensuring high-quality pharmaceuticals has led to a show-cause notice and potential blacklisting for M/s. Effi Parenterals. The action was triggered by the failure of quality tests on specific batches of Albendazole tablets IP 400 mg (Drug Code – D12). Prior to distribution to health institutions, the CGMSCL mandates that all supplied drugs undergo quality testing in NABL-accredited labs. This protocol safeguards the distribution of only tested and approved medicines. The affected batches, namely PGT25451, PGT25450, PGT25480, and PGT25229, were examined at the State Drug Testing and Research Laboratory, Raipur. The substandard test results have prompted the issuance of the blacklisting notice, and Effi Parenterals has been ordered to retrieve the failed batches from all drug storage facilities. The company had previously supplied 14 batches of Albendazole tablets IP 400 mg that passed the quality tests and were distributed to health institutions.